论文部分内容阅读
目的 探讨放射性核素188Re标记抗鼻咽癌 (NPC)单抗BAC5的方法及188Re -BAC5对鼻咽癌进行免疫导向治疗的可行性 .方法 188Re -BAC5的制备采用直接标记法 ,采用MTT法观察188Re -BAC5对体外单层培养的鼻咽癌细胞 (CNE - 2 )的抑制作用 ,对照组为188Re-BSA、188ReO4 -.结果 188Re -BAC5的标记率在 80 %以上 ,MTT法结果表明188Re-BAC5组的抑瘤率比对照组明显提高 (p <0 .0 5 ) .结论 提示188Re -BAC5有可能在对人鼻咽癌的放免导向治疗中起到良好的作用
Objective To investigate the method of 188Re labeled anti-nasopharyngeal carcinoma (NPC) monoclonal antibody BAC5 and 188Re-BAC5 immune-directed therapy of nasopharyngeal carcinoma.Methods 188Re-BAC5 was prepared by direct labeling and MTT assay 188Re - BAC5 on the proliferation of nasopharyngeal carcinoma cells (CNE - 2) cultured in vitro was 188Re - BSA and 188ReO4 - .Results The labeling rate of 188Re - BAC5 was over 80%. The results of MTT showed that 188Re - The tumor inhibition rate of BAC5 group was significantly higher than that of the control group (p <0.05) Conclusion 188Re-BAC5 may play a good role in the radiotherapy-directed therapy of human nasopharyngeal carcinoma